Local Immunomodulatory Strategies to Prevent Allo-Rejection in Transplantation of Insulin-Producing Cells.
Local Immunomodulatory Strategies to Prevent Allo-Rejection in Transplantation of Insulin-Producing Cells.
复制标题
DOI：
10.1002/advs.202003708
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Ma M
中科院分区：
文献类型：
--
作者：
Wang X;Brown NK;Wang B;Shariati K;Wang K;Fuchs S;Melero-Martin JM;Ma M
胰岛移植已显示出作为1型糖尿病（T1 D）的治愈性疗法的前景。然而，全身性免疫抑制的副作用和移植胰岛的长期存活力有限，以及供体器官的稀缺，突出了开发新的、改进的和更安全的细胞替代策略的迫切需要。诱导局部免疫耐受以防止针对胰岛和干细胞衍生的β细胞的同种异体排斥，具有改善移植物功能和拓宽细胞治疗适用性的潜力，同时最大限度地减少全身免疫抑制的不良反应。在这篇小型综述中，讨论了T1 D细胞替代疗法的非包封、局部免疫调节方法的最新进展，包括胰岛/β细胞修饰、免疫调节生物材料平台和免疫调节细胞的共移植。确定了将这些技术转化为临床环境的关键优势和剩余挑战。虽然讨论的许多研究是初步的，但对该领域日益增长的兴趣导致了对涉及细胞工程，免疫治疗和新型生物材料的新组合策略的探索。这种跨学科的研究无疑将加速开发可以使整个T1 D人群受益的疗法。概述了β细胞替代疗法中不同的局部免疫调节方法。胰岛/β细胞修饰的策略与免疫调节蛋白固定在细胞表面或释放到局部微环境，生物材料平台提出或提供免疫调节信号，免疫调节细胞的共移植进行了讨论。
Islet transplantation has shown promise as a curative therapy for type 1 diabetes (T1D). However, the side effects of systemic immunosuppression and limited long‐term viability of engrafted islets, together with the scarcity of donor organs, highlight an urgent need for the development of new, improved, and safer cell‐replacement strategies. Induction of local immunotolerance to prevent allo‐rejection against islets and stem cell derived β cells has the potential to improve graft function and broaden the applicability of cellular therapy while minimizing adverse effects of systemic immunosuppression. In this mini review, recent developments in non‐encapsulation, local immunomodulatory approaches for T1D cell replacement therapies, including islet/β cell modification, immunomodulatory biomaterial platforms, and co‐transplantation of immunomodulatory cells are discussed. Key advantages and remaining challenges in translating such technologies to clinical settings are identified. Although many of the studies discussed are preliminary, the growing interest in the field has led to the exploration of new combinatorial strategies involving cellular engineering, immunotherapy, and novel biomaterials. Such interdisciplinary research will undoubtedly accelerate the development of therapies that can benefit the whole T1D population. An overview of different local immunomodulatory approaches in β cell replacement therapies is provided. Strategies in islet/β cell modification with immunomodulatory proteins immobilized on the cell surface or released to the local microenvironment, biomaterial platforms presenting or delivering immunomodulatory signals, and co‐transplantation of immunomodulatory cells are discussed.
登录
查看更多内容
影响因子：
4.1
作者：
Bailey, R;Griswold, MD
通讯作者：
Griswold, MD
影响因子：
4.9
作者：
Wu H;Ye Z;Mahato RI
通讯作者：
Mahato RI
影响因子：
5.8
作者：
Allen, Riley P.;Bolandparvaz, Amir;Lewis, Jamal S.
通讯作者：
Lewis, Jamal S.
影响因子：
64.8
作者：
BELLGRAU, D;GOLD, D;DUKE, RC
通讯作者：
DUKE, RC
一种工程的宏观囊化膜，将FTY720释放到前提胰岛移植中。
DOI：
10.1002/jbm.b.33862
发表时间：
2018-03
期刊：
Journal of biomedical materials research. Part B, Applied biomaterials
影响因子：
--
作者：
Bowers DT;Olingy CE;Chhabra P;Langman L;Merrill PH;Linhart RS;Tanes ML;Lin D;Brayman KL;Botchwey EA
通讯作者：
Botchwey EA